Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know? - Inês Pereira Amaral; Joana Antunes; Ivânia Soares; Madalena Pupo Correia; Paulo Filipe (Wiley, 2023)